Radiopharm Theranostics (ASX:RAD) has executed a subscription agreement for a private placement of ordinary shares to ...

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will ...

A substantial insider activity was disclosed on December 24, as MARKISON, CEO at Lantheus Holdings LNTH, reported the exercise of a large sell of company stock options. What Happened: MARKISON ...

Two soaring ASX small-cap shares are setting the bar high on Friday. The post 2 ASX small-cap shares rocketing 35% to 54% ...

His departure is amicable and not due to any disagreements, and interim leadership of research and development will be handled by CEO Brian Markison and President Paul Blanchfield while a search ...

In the interim, Lantheus Holdings' CEO Brian Markison and President Paul Blanchfield will oversee the research and development responsibilities previously held by Dr. Humphrey. The company ...

In the interim, Lantheus Holdings' CEO Brian Markison and President Paul Blanchfield will oversee the research and development responsibilities previously held by Dr. Humphrey. The company maintains ...

Lantheus has begun a search for his successor, it said. Chief Executive Brian Markison and President Paul Blanchfield are filling in as interim leaders of research and development.

"This partnership is an important step forward in our purpose to advance our best-in-class radiopharmaceutical therapies," said Brian Markison, CEO of Lantheus. "Radiopharm's deep expertise and ...